RhumbLine Advisers
XERS icon

RhumbLine Advisers’s Xeris Biopharma Holdings XERS Stock Holding History

RhumbLine Advisers’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.7M Buy
214,205
+23,138
+12% +$148K ﹤0.01% 2027
2026
Q1 		$1.11M Buy
191,067
+1,500
+0.8% +$9.95K ﹤0.01% 2146
2025
Q4 		$1.49M Sell
189,567
-24,177
-11% -$190K ﹤0.01% 2032
2025
Q3 		$1.74M Sell
213,744
-1,947
-0.9% -$12.9K ﹤0.01% 1993
2025
Q2 		$1.01M Buy
215,691
+23,410
+12% +$107K ﹤0.01% 2247
2025
Q1 		$1.06M Buy
192,281
+11,317
+6% +$45.7K ﹤0.01% 2146
2024
Q4 		$613K Buy
180,964
+7,408
+4% +$23.8K ﹤0.01% 2535
2024
Q3 		$495K Sell
173,556
-16,414
-9% -$42.2K ﹤0.01% 2702
2024
Q2 		$427K Buy
189,970
+12,332
+7% +$24.9K ﹤0.01% 2784
2024
Q1 		$393K Buy
177,638
+6,346
+4% +$16.4K ﹤0.01% 2808
2023
Q4 		$403K Sell
171,292
-2,516
-1% -$4.64K ﹤0.01% 2793
2023
Q3 		$323K Sell
173,808
-81
-0% -$186 ﹤0.01% 2890
2023
Q2 		$456K Buy
173,889
+1,038
+0.6% +$2.64K ﹤0.01% 2746
2023
Q1 		$282K Buy
172,851
+6,990
+4% +$8.75K ﹤0.01% 2635
2022
Q4 		$221K Buy
165,861
+3,145
+2% +$4.44K ﹤0.01% 2774
2022
Q3 		$254K Buy
162,716
+11,102
+7% +$18.4K ﹤0.01% 2804
2022
Q2 		$233K Buy
+151,614
New +$320K ﹤0.01% 2874
2021
Q2 		– Sell
-41,774
Closed -$188K – 3117
2021
Q1 		$188K Sell
41,774
-1,426
-3% -$7.69K ﹤0.01% 2844
2020
Q4 		$213K Buy
43,200
+5,630
+15% +$28.2K ﹤0.01% 2813
2020
Q3 		$223K Sell
37,570
-7,883
-17% -$31.5K ﹤0.01% 2640
2020
Q2 		$121K Buy
45,453
+14,269
+46% +$49.7K ﹤0.01% 2923
2020
Q1 		$61K Hold
31,184
– – ﹤0.01% 2842
2019
Q4 		$220K Buy
31,184
+349
+1% +$2.88K ﹤0.01% 2719
2019
Q3 		$303K Sell
30,835
-57
-0.2% -$640 ﹤0.01% 2581
2019
Q2 		$353K Buy
30,892
+7,831
+34% +$82.2K ﹤0.01% 2521
2019
Q1 		$232K Buy
+23,061
New +$296K ﹤0.01% 2681

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RhumbLine Advisers's XERS Position: Q2 2026 in Review

RhumbLine Advisers increased its Xeris Biopharma Holdings (XERS) stake by 12% in Q2 2026, buying an estimated $148K and bringing the position to 214,205 shares worth $1.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2027.

RhumbLine Advisers first reported a position in XERS in Q1 2019 and has held it in 26 quarters since. The position peaked at $1.74M in Q3 2025. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • RhumbLine Advisers held 214,205 shares of Xeris Biopharma Holdings worth $1.7M as of Q2 2026.
  • RhumbLine Advisers bought 23,138 Xeris Biopharma Holdings shares in Q2 2026, an estimated $148K.
  • Xeris Biopharma Holdings made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2027 holding.
  • RhumbLine Advisers first reported a position in Xeris Biopharma Holdings in Q1 2019 and has held it in 26 quarters since.
  • RhumbLine Advisers's Xeris Biopharma Holdings position peaked at $1.74M in Q3 2025.
  • 240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.